Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2022-06-15 Transaction in Own Shar…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Transaction in Own Shares' and explicitly states that the company 'announces that it has purchased the following number of its ordinary shares... as part of its Share Buyback Programme'. It details the date, volume, and price of these purchases, and concludes with the resulting treasury share count. This content directly matches the definition of a 'Transaction in Own Shares' report, which corresponds to the filing type code POS (Transaction in Own Shares). The document is a direct report of the transaction, not an announcement of a report's publication.
2022-06-15 English
LYT-300 Achieves Proof-of-Principle in Human Study
Regulatory Filings Classification · 97% confidence The document is a press release dated June 14, 2022, distributed via RNS (indicated by 'RNS Number : 7278O' and the footer mentioning 'Reach, the non-regulatory press release distribution service of RNS'). The content announces a clinical milestone regarding the drug candidate LYT-300 and the Glyph platform, detailing scientific results, expert commentary, and future development plans (Phase 1 completion expected by end of 2022, Phase 1b/2a planned for 2023). This format—a news announcement summarizing recent operational/clinical progress rather than a comprehensive financial report (like 10-K or IR) or a formal regulatory filing detailing specific transactions or votes—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on clinical trial results and platform validation rather than quarterly financial performance highlights, it is best classified as a general announcement. Given the options, 'Regulatory Filings' (RNS) serves as the appropriate fallback for significant, non-financial, non-meeting related corporate news distributed through regulatory channels that doesn't fit a more specific category like DIV, CAP, or MANG. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Report (IR/10-K).
2022-06-14 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from PureTech Health PLC regarding the purchase of its own shares (share buyback). It includes specific details such as the number of shares purchased, price ranges, and a detailed table of individual transactions. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2022-06-14 English
Post-Acute COVID Resp. Complications Topline Data
Regulatory Filings Classification · 99% confidence The document is a press release disseminated via RNS (RNS Number: 7277O) on June 14, 2022. The content announces the results from a Phase 2 study of a drug candidate (LYT-100) for Long COVID, noting no treatment effect was observed in that indication, but reiterating the drug's safety profile and confirming the company's focus on advancing it for Idiopathic Pulmonary Fibrosis (IPF). This structure—announcing clinical trial results, discussing future plans, and providing company/contact details—is characteristic of an Earnings Release (ER) or a general press release. Since it is a specific announcement of periodic financial/clinical results (even if not quarterly earnings), and it is distributed via RNS, it fits best under the 'Earnings Release' (ER) category, which covers initial announcements of periodical results (clinical trial results often serve this function for biotech firms). It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a mere announcement of a report publication (RPA). The presence of the RNS header and the nature of the content strongly suggest an immediate market communication of material results.
2022-06-14 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC, dated June 13, 2022. The title explicitly states 'Transaction in Own Shares' and the content details the purchase of ordinary shares as part of a 'Share Buyback Programme'. This directly corresponds to the definition of a company reporting the repurchase or sale of its own shares. Therefore, the correct classification is Transaction in Own Shares (POS).
2022-06-13 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC dated June 10, 2022. The title explicitly states 'Transaction in Own Shares' and details the purchase of ordinary shares as part of a 'Share Buyback Programme'. This directly corresponds to the definition of a company buying back or selling its own shares. Therefore, the correct classification is Transaction in Own Shares (POS).
2022-06-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.